Coherus Biosciences | CHRS - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Baxter International USD 19.85B 209M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Fujifilm JPY 6.05T 170.69B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Merck USD 128.68B 8.18B 2026-03
Myriad Genetics USD 673.7M 32.9M 2026-03
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 7.98B 551.9M 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xencor USD 736.85M 138.65M 2026-03
Zoetis USD 15.15B 313M 2026-03